Home › Funds › LYNWOOD PRICE CAPITAL MANAGEMENT LP › RPRX
LYNWOOD PRICE CAPITAL MANAGEMENT LP position in RPRX
ROYALTY PHARMA PLC · Health Care
LYNWOOD PRICE CAPITAL MANAGEMENT LP reported holding 183,000 shares of RPRX (ROYALTY PHARMA PLC) in its Q3 2026 13F filing — a position valued at US$10.7M, representing 5.54% of its reported portfolio and ranking #10 among its reported holdings. LYNWOOD PRICE CAPITAL MANAGEMENT LP has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How LYNWOOD PRICE CAPITAL MANAGEMENT LP's RPRX position evolved
LYNWOOD PRICE CAPITAL MANAGEMENT LP first disclosed a stake in RPRX in Q2 2026 at 143,000 shares (US$8.0M). The position peaked in Q3 2026 at 183,000 shares, worth US$10.7M. Across 2 filings, LYNWOOD PRICE CAPITAL MANAGEMENT LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 183,000 shares valued at US$10.7M — an increase of 40,000 shares quarter over quarter.. Notable position changes include a 28% increase in Q3 2026 (shares rose 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 143.00K | $8.02M | New |
| Q3 2026 | 183.00K | $10.68M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 48 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$598.8M), Baillie Gifford & Co (US$534.1M), ROYAL LONDON ASSET MANAGEMENT LTD (US$348.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.26M sh · $598.81M · Q3 2026
- Baillie Gifford & Co 9.15M sh · $534.11M · Q3 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 5.97M sh · $348.63M · Q3 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- Patient Capital Management, LLC 3.42M sh · $199.71M · Q3 2026
- Dorsey Asset Management, LLC 2.46M sh · $137.74M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $96.68M · Q3 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 1.45M sh · $84.36M · Q3 2026
More on LYNWOOD PRICE CAPITAL MANAGEMENT LP
FAQ
How long has LYNWOOD PRICE CAPITAL MANAGEMENT LP held RPRX?
LYNWOOD PRICE CAPITAL MANAGEMENT LP has disclosed RPRX holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is LYNWOOD PRICE CAPITAL MANAGEMENT LP's current position in RPRX?
As of Q3 2026, LYNWOOD PRICE CAPITAL MANAGEMENT LP holds 183.00K shares of RPRX (ROYALTY PHARMA PLC), valued at $10.68M, representing 5.54% of its reported portfolio and ranking #10.
Has LYNWOOD PRICE CAPITAL MANAGEMENT LP been buying or selling RPRX?
In the latest 13F filing (Q3 2026), LYNWOOD PRICE CAPITAL MANAGEMENT LP increased its position in RPRX. The position peaked in Q3 2026 at 183.00K shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, ROYAL LONDON ASSET MANAGEMENT LTD, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.